title: [Treatment with intravenous rt-PA in a general hospital context: A review of the Saint-Jean Hospital experience from Perpignan, France].
abstract: BACKGROUND
  Intravenous recombinant tissue plasminogen activator (rt-PA) has approval for use despite of its authorization for treatment of ischemic stroke within the 3-hour time window in 2003, is rarely used in community hospital (CH). It therefore remains questionable if the positive results of the key studies conducted in specialized centers may be extended to community hospitals less specialized in the management of stroke.
  
  
  METHODS
  We report the results of an observational cohort study including 39 patients treated with intravenous rt-Pa (according to the NINDS rt-PA stroke trail treatment protocol) at St Jean Hospital (Perpignan, France) between March 1, 2002 and August 31, 2005. Results are compared to those of the treated arm of the NINDS study.
  
  
  RESULTS
  1.2p.cent of ischemic stroke were treated with intravenous rt-Pa. Results are similar to those of the NINDS study: The outcome was favorable (modified Rankin score (mRS) with 0 or 1) for 44p.cent of the patients (as compared to 39p.cent in the NINDS study (X2 = 0.34; p = 0.5)) and there was no significant difference in term of death or outcome as assessed by mRS at 3 months (X2 = 0.09; p = 0.75 and X2 = 0.77; p = 0.75, respectively). No symptomatic hemmorrhagic transformation related to the use of rt-Pa was observed.
  
  
  CONCLUSIONS
  Our results indicate that rt-PA therapy for ischemic stroke may be as safe and effective in the setting of a community hospital as it is in specialized centers.
authors.affiliation: Service de Neurologie, Hôpital Saint-Jean, Perpignan. denis.sablot@ch-perpignan.fr
authors.forename: D
authors.initials: D
authors.lastname: Sablot
authors.forename: J-F
authors.initials: JF
authors.lastname: Cassarini
authors.forename: A
authors.initials: A
authors.lastname: Akouz
authors.forename: J-M
authors.initials: JM
authors.lastname: Benejean
authors.forename: F
authors.initials: F
authors.lastname: Leibinger
authors.forename: X
authors.initials: X
authors.lastname: Faillie
authors.forename: E
authors.initials: E
authors.lastname: Vidry
authors.forename: X
authors.initials: X
authors.lastname: Ayrignac
authors.forename: S
authors.initials: S
authors.lastname: Castro
authors.forename: L
authors.initials: L
authors.lastname: Sinaya
authors.forename: J-L
authors.initials: JL
authors.lastname: Bertrand
authors.forename: Y
authors.initials: Y
authors.lastname: Garcia
authors.forename: B
authors.initials: B
authors.lastname: Arnoud
authors.forename: C
authors.initials: C
authors.lastname: Negre
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy; D002543:Cerebral Hemorrhage / Q000188:drug therapy / Q000453:epidemiology; D015331:Cohort Studies; D005260:Female; D006764:Hospitals, Community; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator